NEW YORK CITY, NY / ACCESS Newswire / June 16, 2026 / Levi & Korsinsky notifies investors that it has commenced an investigation into Elicio Therapeutics, Inc. ("Elicio Therapeutics, Inc.") (NASDAQ:ELTX) concerning potential violations of the federal securities laws. On June 9, the Company reported Q1 2026 earnings showing zero revenue and a widening net loss driven by R&D spending. Six days later, shares collapsed. The Q1 2026 filing showed the Company generated no product revenue while reporting increased research and development expenses tied to the AMPLIFY-7P program. The Company's cash position funded operations centered on ELI-002 7P as its lead pipeline candidate. On June 15, the 144-patient Phase 2 trial missed its pre-specified primary endpoint. Days before the trial data became public, B. Riley Securities had issued a Buy rating with a $27 price target on June 10-11. The stock closed at only $4.08 after the Phase 2 miss was disclosed on June 15. If you suffered a loss on your Elicio Therapeutics, Inc. securities and would like to explore a potential recovery under the federal securities laws, Learn More About the Investigation or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or call (212)363-7500 to speak to our team of experienced shareholder advocates. WHY LEVI & KORSINSKY: Over the past 20 years, Levi & Korsinsky LLP has established itself as a nationally-recognized securities litigation firm that has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. The firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report as one of the top securities litigation firms in the United States. Attorney Advertising. Prior results do not guarantee similar outcomes. CONTACT:Levi & Korsinsky, LLPJoseph E. Levi, Esq.Ed Korsinsky, Esq.33 Whitehall Street, 27th FloorNew York, NY 10004jlevi@levikorsinsky.comTel: (212)363-7500Fax: (212)363-7171 SOURCE: Levi & Korsinsky, LLP View the original press release on ACCESS NewswireCOMTEX_484001675/2457/2026-06-16T12:52:04 | 
37.35% $1.92
